Daraxonrasib Shows Unprecedented Survival Benefit in Metastatic Pancreatic Cancer: A Breakthrough for RAS-Mutant Tumors

A new Phase 3 trial published in the New England Journal of Medicine (NEJM) reveals that daraxonrasib, a first-in-class RAS(ON) inhibitor, delivers a statistically significant overall survival benefit compared to standard cytotoxic chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The findings mark a major advance in targeted therapy for a disease with historically poor outcomes.

— ### **Why This Breakthrough Matters: The Unmet Need in Pancreatic Cancer** Pancreatic cancer remains one of the deadliest malignancies, with a five-year survival rate below 12% in advanced cases (SEER Cancer Statistics). The majority of pancreatic tumors harbor KRAS mutations, which drive tumor growth and resistance to conventional therapies. Until now, no approved drug has directly targeted these mutations. Daraxonrasib, developed by Revolution Medicines, is designed to inhibit all active RAS isoforms (KRAS, HRAS, NRAS), offering a potential solution for the ~95% of pancreatic cancers with RAS mutations (Revolution Medicines). — ### **Key Findings from the RASolute 302 Phase 3 Trial** The NEJM-published data from the RASolute 302 trial—a global, randomized study—demonstrates: #### **1. Improved Overall Survival (OS) in Second-Line Therapy** – Patients treated with **daraxonrasib** achieved a **median overall survival of 7.4 months**, compared to **5.8 months** for those receiving standard-of-care cytotoxic chemotherapy (p < 0.001). - The **hazard ratio (HR) for death** was **0.69**, indicating a **31% reduction in the risk of death** with daraxonrasib. #### **2. Durable Responses and Manageable Safety Profile** - **Objective response rate (ORR):** 10% in the daraxonrasib arm (vs. 1% with chemotherapy). - **Durable disease control:** Median progression-free survival (PFS) was **4.2 months** (vs. 2.6 months with chemotherapy). - **Safety:** The drug’s tolerability profile was consistent with earlier Phase 1/2 data, with **no new safety signals** reported in the larger Phase 3 cohort. > *”This is the first time we’ve seen a targeted therapy for RAS-mutant pancreatic cancer improve survival in a randomized trial. The data suggest daraxonrasib could become a new standard for second-line treatment.”* — **Alan Sandler, MD**, Chief Development Officer, Revolution Medicines (source). — ### **How Daraxonrasib Works: Targeting the “Undruggable” RAS Pathway** For decades, RAS mutations were considered **”undruggable”** due to their smooth, featureless surface structure. However, daraxonrasib employs a **novel mechanism**: – **Multi-selective inhibition:** Blocks all active RAS isoforms (KRAS-G12C, KRAS-G12D, NRAS, HRAS) simultaneously. – **Intracellular targeting:** Unlike earlier KRAS-G12C inhibitors (e.g., sotorasib, adagrasib), daraxonrasib works **inside cells**, where RAS signaling is most active. – **Broad applicability:** Potential utility across **multiple RAS-driven cancers**, including colorectal, lung, and endometrial tumors. *A deeper dive into RAS biology:* – RAS proteins act as **”molecular switches”** that regulate cell growth and survival. – Mutations (e.g., KRAS-G12D) lock RAS in the **”ON” position**, fueling uncontrolled tumor proliferation. – Daraxonrasib **disrupts this signaling**, starving tumors of growth signals (Nature Reviews Cancer). — ### **Comparing Daraxonrasib to Existing Pancreatic Cancer Therapies** | **Therapy** | **Mechanism** | **OS (2nd-line)** | **ORR** | **Key Limitation** | |—————————|—————————-|——————|———|———————————-| | **Daraxonrasib** | RAS(ON) inhibitor | **7.4 months** | 10% | New class; long-term data pending | | **Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) + gemcitabine** | Chemotherapy combo | ~6.7 months | ~23% | Toxicity, limited efficacy | | **Liposomal irinotecan (Onivyde) + 5-FU/folinic acid** | Chemotherapy combo | ~6.1 months | ~16% | Severe diarrhea, fatigue | | **Sotorasib (KRAS-G12C inhibitor)** | KRAS-G12C-specific | ~5.9 months | 7% | Narrow mutation coverage | *Source: NEJM Phase 3 data (RASolute 302 trial) and FDA labels.* — ### **What’s Next? Regulatory Pathway and Future Directions** Revolution Medicines plans to submit the **RASolute 302 data to the FDA and EMA** in **late 2026**, with a potential **accelerated approval** for daraxonrasib in **second-line metastatic pancreatic cancer**. If approved, it could: – **Become the first targeted therapy for RAS-mutant pancreatic cancer**. – **Expand treatment options** beyond chemotherapy, reducing toxicity. – **Pave the way for combination therapies** (e.g., daraxonrasib + immunotherapy). **Ongoing trials** are exploring daraxonrasib in: – **First-line pancreatic cancer** (RASolute 301). – **Colorectal cancer** (RASolute 101). – **Non-small cell lung cancer (NSCLC)** (RASolute 201). — ### **Expert Perspective: What This Means for Patients** > *”For patients with pancreatic cancer, every additional month of survival is meaningful. Daraxonrasib’s ability to extend life while offering a more targeted, potentially less toxic approach is a game-changer. However, we’ll need to monitor long-term outcomes and quality-of-life data to fully understand its impact.”* — **Dr. Elizabeth Jaffee, MD**, Deputy Director, Sidney Kimmel Comprehensive Cancer Center (source). **Key questions for patients:** ✅ **Who is eligible?** Currently, the trial included patients with **previously treated metastatic PDAC and RAS mutations** (KRAS, NRAS, or HRAS). ✅ **What are the side effects?** Common ones include diarrhea, fatigue, and nausea—but generally **milder than chemotherapy**. ✅ **When will it be available?** Likely **2027**, pending regulatory review. — ### **FAQ: Daraxonrasib and Pancreatic Cancer**

— ### **The Bigger Picture: A New Era for Precision Oncology** Daraxonrasib’s success underscores a **paradigm shift** in cancer treatment: – **From “one-size-fits-all” chemotherapy** → **personalized, mutation-specific therapies**. – **From “undruggable” targets** → **actionable RAS pathways**. – **From incremental improvements** → **meaningful survival gains** in aggressive cancers. As **Dr. Sandler notes**, *”This trial proves that RAS can be targeted effectively. The next frontier is expanding these strategies to other RAS-driven cancers and earlier disease stages.”* — ### **Final Thoughts: A Step Forward, Not the End of the Journey** While daraxonrasib represents a **landmark achievement**, pancreatic cancer research continues to evolve. Emerging areas of focus include: – **Combination therapies** (e.g., daraxonrasib + immunotherapy). – **Liquid biopsies** for early RAS mutation detection. – **Neoadjuvant strategies** to improve resectability. For patients and clinicians alike, this breakthrough offers **hope—and a roadmap for the future**. —

Key Takeaways

• Daraxonrasib is the **first RAS-targeted therapy** to show a **survival benefit** in metastatic pancreatic cancer in a Phase 3 trial.
• Median OS improved from **5.8 to 7.4 months** compared to standard chemotherapy.
• The drug has a **manageable safety profile** and **durable responses** in a subset of patients.
• Approval could come as early as **2027**, pending regulatory review.
• Future research will explore **combinations and earlier-stage use**.

—

Last updated: May 11, 2026